Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (MASTER-2)

– Signed informed consent

– Have diagnosis of RMS, including RRMS and aSPMS, and satisfy the approved indication
for cladribine tablets as per United States Prescribing Information (USPI)

– Have time since diagnosis of RMS of at least 12 months

– In the opinion of the investigator, experienced suboptimal response (lack of
effectiveness, intolerability, poor adherence) to oral or infusion DMD treatment other
than cladribine tablets

– Had received their last previous oral DMD for at least 3 months

– Have decided to initiate treatment with cladribine tablets during routine clinical
care

– Meet criteria as per the approved USPI

– Have access to a valid e-mail address

Exclusion Criteria:

– Have been previously treated with cladribine in any dosing form (intravenous,
subcutaneous, or oral)

– Transitioning from previous oral DMD solely for administrative reasons such as
relocation

– Have comorbid conditions that preclude participation

– Have any clinical condition or medical history noted as contraindication on USPI

– Are currently participating in an interventional clinical trial

– Pregnant or breastfeeding women, women who plan to become pregnant or men whose
partner plans to become pregnant during study the cladribine treatment period